• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Recruitment begins in Mozambique for ANTICOV clinical trial of early treatments for COVID-19

The availability of drugs to prevent mass hospitalisation is a priority for Africa

Home > Stories

Recruitment begins in Mozambique for ANTICOV clinical trial of early treatments for COVID-19

The availability of drugs to prevent mass hospitalisation is a priority for Africa

Healthcare workers in a lab setting
29 Jul 2021

This story was published by ISGlobal on 27 July 2021 and is available in English, Spanish, and Catalan.

The two centres in Mozambique that ISGlobal is working with on the large-scale ANTICOV clinical trial have started recruiting participants, following in the footsteps of the Democratic Republic of the Congo, Ghana, Guinea, Kenya, and Mali. The aim of the trial, which is being conducted in 13 African countries, is to find an effective treatment to prevent progression of mild or moderate COVID-19 to severe disease.

ANTICOV will test different treatments. One of them is a combination of nitazoxanide, a well-known anti-parasitic drug that would be administered for its potential antiviral effect, and ciclesonide, an inhaled corticosteroid with an anti-inflammatory effect. Both drugs are already commercially available, affordable, safe, and easy to administer.

The Manhiça Health Research Centre (CISM) and the Polana Caniço Health Research and Training Centre (CISPOC), which is affiliated with Mozambique’s National Institute of Health, are ramping up their recruitment processes as the incidence of COVID-19 increases rapidly across Mozambique.

‘We are at the peak of COVID-19, with two main hotspots, one in the capital city of Maputo and the other in the north-western province of Tete,‘ explained Patricia Pérez, Paediatrician and Coordinator of ANTICOV in Mozambique. The predominant viral variant is now Delta, although the South African variant also continues to circulate. Meanwhile, just 1% of Mozambique’s population is fully vaccinated. ‘With more than 1,000 new cases and 15-20 deaths each day, diagnostic services are starting to be overloaded, hospital beds for COVID-19 patients are running out and oxygen supplies are becoming scarce,‘ Pérez continued.

It is important to remember that the intensive care infrastructure is limited in Africa and that the continent’s health systems are weak and already under pressure due to other infectious diseases. ‘In addition, physical isolation and quarantines are practically impossible,‘ added Elisa López, ANTICOV’s Co-Principal Investigator in Mozambique.

After Mozambique, the project is preparing to start recruiting soon in Côte d’Ivoire, Ethiopia, and Burkina Faso. ‘Altogether, across all of the countries, we expect to have 300 participants by the end of August and we hope to announce the initial results of the trial at that time,‘ commented Laura de la Fuente, Project Manager for ANTICOV in Mozambique.

In the coming days, recruitment will also begin in Mozambique for an immunological trial—one of ANTICOV’s two ancillary studies—that ISGlobal is co-leading with Belgium’s Institute of Tropical Medicine Antwerp (ITM). This study will be conducted in six countries and aims to analyse whether the treatments tested in the clinical trial in patients with mild or moderate COVID-19 alter the strength and duration of the immune response to SARS-CoV-2. ‘Knowing how long immunity lasts is especially important in Africa, where vaccination levels are very low,’ commented Gemma Moncunill, an immunologist at ISGlobal and Scientific Coordinator of the study.

26-Member Consortium

ANTICOV is a consortium of 26 prominent research and development organisations, including ISGlobal, a centre supported by the ”la Caixa” Foundation. The project is coordinated by the Drugs for Neglected Diseases initiative (DNDi). ANTICOV is a flexible and innovative “adaptive platform trial” that allows treatments to be added or removed from the study as more knowledge is gained about them.

Information for the selection of drugs to test in the ANTICOV trial is obtained from reviews conducted by the Access to COVID-19 Tools Accelerator (ACT-A) Therapeutics Partnership, which is co-convened by Unitaid and the Wellcome Trust.

Major funding for the ANTICOV consortium is provided by the global health agency Unitaid as part of ACT-A and by the German Federal Ministry of Education and Research through KfW. It is also supported by the European & Developing Countries Clinical Trials Partnership (EDCTP), the Starr International Foundation, and the Stavros Niarchos Foundation (SNF).

Photo credits: Gemma Moncunill / ISGlobal, CISM / ISGlobal

Clinical trials Partnership Pandemic Preparedness Africa

Read, watch, share

Loading...
Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License